UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States

Annals of internal medicine, 2015-03, Vol.162 (6), p.397-406

2015

Volltextzugriff (PDF)

Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis

PLoS medicine, 2016-05, Vol.13 (5), p.e1002032-e1002032

2016

Volltextzugriff (PDF)

Cost-effectiveness of novel regimens for the treatment of hepatitis C virus

Annals of internal medicine, 2015-03, Vol.162 (6), p.407-419

2015

Volltextzugriff (PDF)

Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

Alimentary pharmacology & therapeutics, 2015-03, Vol.41 (6), p.544-563

2015

Volltextzugriff (PDF)

Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study

Journal of hepatology, 2017-06, Vol.66 (6), p.1123-1129

2017

Volltextzugriff (PDF)

New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners

Health Affairs, 2016-10, Vol.35 (10), p.1893-1901

2016

Volltextzugriff (PDF)

Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis

Nature communications, 2014-11, Vol.5 (1), p.5606-5606, Article 5606

2014

Volltextzugriff (PDF)

The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis

Transplantation, 2017-05, Vol.101 (5), p.987-995

2017

Volltextzugriff (PDF)

Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade

PloS one, 2015-08, Vol.10 (8), p.e0135645-e0135645

2015

Volltextzugriff (PDF)

Cost-effectiveness of Oral Regimens for Adolescents With Chronic Hepatitis C Virus Infection

The Pediatric infectious disease journal, 2020-06, Vol.39 (6), p.e59-e65

2020

Volltextzugriff (PDF)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany

PloS one, 2017-01, Vol.12 (1), p.e0169401-e0169401

2017

Volltextzugriff (PDF)

Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C

The American journal of managed care, 2016-05, Vol.22 (6 Spec No.), p.SP205-SP211

2016

Volltextzugriff (PDF)

Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma

Transplantation, 2017-05, Vol.101 (5), p.1001-1008

2017

Volltextzugriff (PDF)

Experience With the Priority Review Voucher Program for Drug Development

JAMA : the journal of the American Medical Association, 2015-10, Vol.314 (16), p.1687

2015

Volltextzugriff (PDF)

Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients

Value in health, 2016-06, Vol.19 (4), p.326-334

2016

Volltextzugriff (PDF)

Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US

BMC gastroenterology, 2015-08, Vol.15 (1), p.98, Article 98

2015

Volltextzugriff (PDF)

The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized controlled trial

PLoS medicine, 2011-05, Vol.8 (5), p.e1000437

2011

Volltextzugriff (PDF)

A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan

Advances in therapy, 2020-01, Vol.37 (1), p.457-476

2020

Volltextzugriff (PDF)

High cost of new drugs

BMJ (Online), 2016-07, Vol.354, p.i4136

Mazzucato, Mariana

2016

Volltextzugriff (PDF)

An Economic Evaluation of the Posttreatment Prophylactic Effect of Dihydroartemisinin-Piperaquine Versus Artemether-Lumefantrine for First-Line Treatment of Plasmodium falciparum Malaria Across Different Transmission Settings in Africa

The American journal of tropical medicine and hygiene, 2015-11, Vol.93 (5), p.961-966

2015

Volltextzugriff (PDF)

Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania

PloS one, 2009-09, Vol.4 (9), p.e6857-e6857

2009

Volltextzugriff (PDF)

Cost‐effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis

Journal of viral hepatitis, 2017-09, Vol.24 (9), p.750-758

2017

Volltextzugriff (PDF)

Gilead injects own generics into shrinking HCV drug market

Nature biotechnology, 2018-11, Vol.36 (11), p.1030-1030

Morrison, Christopher

2018

Volltextzugriff (PDF)

Treating Medicaid patients with hepatitis C: clinical and economic impact

The American journal of managed care, 2017-02, Vol.23 (2), p.107-112

2017

Volltextzugriff (PDF)

1 – 25 von 201

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(188)
Mit Volltextzugriff
(166)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States

Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis

Cost-effectiveness of novel regimens for the treatment of hepatitis C virus

Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study

New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners

Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis

The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis

Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade

Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data

Cost-effectiveness of Oral Regimens for Adolescents With Chronic Hepatitis C Virus Infection

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany

Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C

Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma

Experience With the Priority Review Voucher Program for Drug Development

Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients

Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US

The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized controlled trial

A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan

High cost of new drugs

An Economic Evaluation of the Posttreatment Prophylactic Effect of Dihydroartemisinin-Piperaquine Versus Artemether-Lumefantrine for First-Line Treatment of Plasmodium falciparum Malaria Across Different Transmission Settings in Africa

Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania

Cost‐effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis

Gilead injects own generics into shrinking HCV drug market

Treating Medicaid patients with hepatitis C: clinical and economic impact

Suchergebnisse filtern